Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Ok, ham as it may be, the calculations are based weekly low-high returns.

What I mean by this is I took the low from the weekly lowest low just after the first Phase I results 10-16-98. Then the high from the highest weekly high 02-05-99. Those two figures ($28.00 / $3.50=8, 8-1=7) the difference between the two. Applied that finding to the present data. (Lowest weekly low 04-23-99; $10.75 X 7=75.25) Also, applying similar data findings from Immunex (A similar pharmaceutical research co) and came up with the figure $56.00 a share.

This is NOT definite! The stock may or may not reach $56.00 a share after the projected release in late January, early February. That projection is based on good, encouraging news.

However, the company is run by a very good team of professionals and the stock is being picked up by investment funds. (That stabilizes the stock price.)

I will also say that like, Immunex, the stock will rocket when either T-20 or T-1249 is brought to market. That is after the products have gone through successful FDA tests. That is where the gamble is, will Trimeris's products succeed?

I personally hope they will. Their concepts in medicine are radical yet make complete sense to me. I am however, not a doctor nor am I fighting HIV.

After reviewing their projected projects and their past performance I feel good will and I am betting they will succeed!

That is my two cents. (If it is worth that much.)

Fool on!
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.